|
| | R-(-)-Apomorphine Basic information |
| Product Name: | R-(-)-Apomorphine | | Synonyms: | (r)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo[de,g]quinoline-10,11-diol;Apomorphine hydrochloride R-(-)-;(6Ar)-5,6,6A,7-tetrahydro-6-methyl-4H-dibenzo(de,G)chinolin-10,11-diol hydrochlorid;6a-beta-aporphine-10,11-diol;APOMORPHINE HYDROCHLORIDE, HEMIHYDRATE;4H-Dibenzode,gquinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, hydrate (2:1), (6aR)-;APOMORPHINEHCLHEMIHYDRATE;APOMORPHINEHYDROCHLORIDE,HEMIHYDRATE,USP | | CAS: | 41372-20-7 | | MF: | C17H20ClNO3 | | MW: | 321.8 | | EINECS: | 627-402-4 | | Product Categories: | Inhibitors;APOKYN;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Erectile Dysfunction;Agonists;Dopaminergics;Neurotransmitters;Dopamine receptor | | Mol File: | 41372-20-7.mol |  |
| | R-(-)-Apomorphine Chemical Properties |
| Melting point | 285-287 °C(lit.) | | alpha | -48 º (c=1, H2O) | | storage temp. | Refrigerator | | solubility | H2O: ~10 mg/mL, clear, yellow-green | | form | calcined | | color | white to gray | | PH | pH(10g/l, 25℃) : 4.0～5.0 | | Merck | 13,751 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 1 week. | | CAS DataBase Reference | 41372-20-7(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 36 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | HS Code | 2933997000 |
| | R-(-)-Apomorphine Usage And Synthesis |
| Description | Apomorphine (41372-20-7) is an archetypal dopamine pan-receptor agonist. Displays anti-Parkinsons activity in vivo.1 Protects against MPTP-induced neurotoxicity in a mouse mode1,2 In clinical use for Parkinson’s disease.4,5 | | Chemical Properties | Off-White Solid | | Uses | emetic, antiparkinsonian, erextile dysfunction therapy | | Uses | Dopamine (D1 and D2) receptor agonist. Emetic. Antiparkinsonian. | | Uses | R-(?)-Apomorphine hydrochloride hemihydrate is a nonselective dopamine agonist with anti-Parkinsonian and neuroprotective effects in vivo. | | Brand name | Apokyn
(Vernalis). | | Purification Methods | Crystallise the salt from H2O (hemihydrate) and from EtOH. Crystals turn green on exposure to light. (see previous entry). NARCOTIC. | | References | 1) Merck Index 14:746
2) Millan et al. (2002), Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes; J. Pharmacol. Exp. Therap., 303 791
3) Grunblatt et al. (1999), Apomorphine protects against MPTP-induced neurotoxicity in mice.; Mov. Discord, 14 612
4) Auffret et al. (2017), Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations; J. Neurol. Sci, 372 279
5) Jenner and Katzenschlager (2016), Apomorphine – pharmacological properties and clinical trials in Parkinson’s disease; Parkinsonism. Related. Disord., 33 Suppl. 1:S13 |
| | R-(-)-Apomorphine Preparation Products And Raw materials |
|
